The era of off-label guesswork for patients living with the rare autoimmune disorder MOGAD may soon be over, as a phase 3 ...

Baum is transitioning from his role as Pfizer’s chief strategy and innovation officer to serve as a senior strategic advisor ...

After prevailing in two kidney cancer trials in the refractory and early-stage settings, Merck & Co.’s blockbuster prospect ...

Already approved to treat four rare diseases, AstraZeneca’s Ultomiris has shown its ability against another rare disorder, ...

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease that can cause muscle weakness, fatigue and problems ...

Sanofi’s protein-based vaccine Nuvaxovid has conquered Moderna’s next-generation messenger RNA shot mNexspike in a ...

Biovac has secured a $108.3 million financing package that will allow the South African pharma company to build the continent ...

In a blow to Bayer, a U.S. federal judge in Manhattan has said he will not block Johnson & Johnson’s survival claims on a key ...

Theramex has opted out of the U.K.’s self-regulatory program for pharma ma | Theramex has opted out of the U.K.’s ...

Genentech has launched the “Life Doesn’t Wait” campaign to mark World Hemophilia Day, dialing up its focus on patient stories ...

AbbVie is running a new psoriasis campaign based on feedback from real patients about how the condition affects their daily ...

Neurogene is looking to make the leap from a clinical biotech to a commercial biopharma with its lead gene therapy and has ...